The Conversation (0)
BrainStorm Cell Therapeutics (OTCQB:BCLI) was granted a key patent for its autologous stem cell technology by the U.S. Patent and Trademark Office. Patent No. 8,663,987 covers the Company’s proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
BrainStorm Cell Therapeutics (OTCQB:BCLI) was granted a key patent for its autologous stem cell technology by the U.S. Patent and Trademark Office. Patent No. 8,663,987 covers the Company’s proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
As quoted in the press release:
Pending approval from the FDA, the company is currently preparing for its upcoming multi-center Phase II trial in the U.S. with its proprietary NurOwn™ stem cell therapy, which was developed with these cells.
Click here to read the BrainStorm Cell Therapeutics (OTCQB:BCLI) press release
